Patients with depression may develop atherosclerotic cardiovascular disease earlier and start treatment more often than those ...

The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

More than 70% of people over 70 years old will one day develop cardiovascular disease, highlighting the need for effective ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of cardiovascular death worldwide—in large mammals, a study suggests. DT-109 ...

Cardiovascular disease is the leading cause of death worldwide and often originates in atherosclerosis, a chronic condition in which inflammation and fat deposits cause arteries to harden and narrow.

Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...

Please provide your email address to receive an email when new articles are posted on . Lp(a) was linked to increased risk for PAD, major adverse limb events and carotid stenosis. Lp(a) may be a ...